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liver disease via MAPK-JNK/P38 signaling in
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Abstract
Background: Melatonin can regulate lipid metabolism, increase insulin sensitivity, regulate glucose metabolism and
reduce body weight. This study is aimed to determine the effects and mechanism of action of melatonin on
non-alcoholic fatty liver disease (NAFLD) in high-fat-diet (HFD) induced obese mice.
Methods: NAFLD was induced by HFD in C57BL/6 mice. A total of 24 mice were randomly assigned to 4 groups.
Groups A and B were fed with HFD for 36 weeks while groups C and D were fed with a regular diet (RD). During
the last 12 weeks, Groups A and C were treated with 10 mg/kg melatonin while Groups B and D were treated with
water in the same volume by intragastric administration. Body and liver weight, blood glucose, serum
transaminases and lipid levels, and markers of hepatic inflammation were measured. Histological analyses were also
performed on liver tissue.
Results: After 12 weeks of treatment with melatonin, body weights (Group A: before 53.11 ± 0.72 vs after 12w
treatment 39.48 ± 0.74) and liver weights (A 1.93 ± 0.09 g vs B 2.92 ± 0.19 g vs C 1.48 ± 0.09 g vs D 1.49 ± 0.10 g),
fasting plasma glucose, alanine transaminase (A 24.33 ± 11.90 IU/L vs B 60.80 ± 10.18 IU/L vs C 13.01 ± 3.49 IU/L
vs D 16.62 ± 2.00 IU/L), and low-density cholesterol (A 0.24 ± 0.06 mmol/L vs B 1.57 ± 0.10 mmol/L vs C 0.28 ± 0.
06 mmol/L vs D 0.29 ± 0.03 mmol/L) were significantly decreased in HFD mice. HFD fed mice treated with
melatonin showed significantly less liver steatosis. Treatment of HFD fed mice with melatonin led to a significant
decrease in the expression of TNF-α, IL-1β, and IL-6 measured using quantitative real-time polymerase chain
reaction (qRT-PCR). HFD fed mice demonstrated increased phosphorylation of P38 and JNK1/2, which was reduced
by melatonin treatment.
Conclusions: The study concluded that melatonin could improve NAFLD by decreasing body weight and reduce
inflammation in HFD induced obese mice by modulating the MAPK-JNK/P38 signaling pathway.
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Background
Non-alcoholic fatty liver disease (NAFLD) is character-
ized by fat accumulation in hepatocytes and precedes
hepatic steatosis and occurs in the absence of alcohol
consumption [1]. NAFLD is a growing public health
concern worldwide because of its high morbidity and its
association with hyperlipidemia, diabetes, and obesity [1,
2]. Simple steatosis occurs early in the course of NAFLD
and progresses to nonalcoholic steatohepatitis (NASH)
and finally to liver cirrhosis [3]. Obesity is an important
risk factor driving the development of NAFLD [4]. A
high-fat-diet (HFD) may act as the ‘first hit’ leading to
NAFLD while inflammation likely serves as a ‘second
hit’ driving progression from NAFLD to NASH [5].
Currently, treatment for NAFLD is mainly aimed at
modifying risk factors, but there are no therapies directly
targeting underlying liver pathology [6].
Melatonin is a hormone secreted by the pineal gland.
The synthesis and secretion of melatonin are regulated
by light intensity [7]. It has been demonstrated that
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melatonin has multiple biological effects and acts as an
anti-oxidant [8, 9]. It has anti-inflammatory properties
[10, 11], regulates circadian rhythms [12] and immunity
[13]. It also has anti-neoplastic effects [14]. Recent
research has also found that melatonin can regulate lipid
metabolism [15], increase insulin sensitivity [16], regulate
glucose metabolism [17], and reduce body weight [18]. It
was found that melatonin could improve HFD-induced
NAFLD and attenuate oxidative stress [19]. Stacchiotti et
al. also found that melatonin treatment could improve
hepatic macrosteatosis in NAFLD in ob/ob mice [20].
However, the underlying mechanisms remain unclear.
This study was designed to investigate the effect of




24 male C57BL/6 mice (6 weeks old, 21.32 ± 0.85 g)
were purchased from Shanghai SLAC Laboratory
Animal Co. Ltd (Shanghai, China). The mice were
housed in a clean room maintained at 24 ± 2 °C under a
12 h:12 h light:dark cycle, with free access to food and
water. All animal experiments were approved by the
Animal Care and Use Committee of Tongji University
with the Ethics Protocol number QS20140305. Mice
were randomly assigned to 4 groups. Group A (n = 6)
and Group B (n = 6) were fed with HFD for 36 weeks,
while Group C and Group D were fed with regular diet
(RD). After 24 weeks, Group A and Group C received
10 mg/kg melatonin by intragastric administration
while Group B and Droup D received double-distilled
water in same volume by intragastric administration
consistently between 7 pm and 8 pm for 12 weeks,
according to previous studies [19, 21–23]. HFD and RD
were purchased from Meidisen Biomedical Company
(Jiangsu, China). The diets follow the AIN93 recom-
mendations. The high fat diet (research diet D12492)
contains 60% calories from fat, 20% from carbohydrates
and 20% from proteins. The regular diet (research diet
D12450B) contains 10% calories from fat, 70% from
carbohydrates and 20% from proteins. Melatonin was
purchased from Sigma Aldrich Chemical Co. (St. Louis,
MO, USA), dissolved in water. The ethanol concentra-
tion in the final solution was 1%. At the end of the
experimental time period, mice were anaesthetized
using pentobarbital sodium, blood was collected via
cardiac puncture, and livers were removed upon
sacrifice.
Body weight and liver weight evaluation
Body weight was measured every 4 weeks consistently
between 7 pm and 8 pm. Liver weight was measured
after sacrifice.
Blood glucose, transaminase and lipid levels
Blood glucose was determined after tail-snip and
measured using a glucose test strip reader. Serum levels
of alanine aminotransferase (ALT) and aspartate amino-
transferase (AST), triglycerides (TG), low-density choles-
terol (LDL-C) and high-density cholesterol (HDL-C)
were measured spectrophotometrically according to the
instructions (NJJCBIO, Jiangsu, China).
Histological analyses
Paraffin sections of liver, 4 μm thick, were processed for
hematoxylin-eosin (HE) staining. Frozen sections of liver,
8 μm thick, were processed routinely for Oil Red O
staining.
Volume density (Vv) of hepatic steatosis was analyzed
using the software Image Pro Plus, version 7.01 for
Windows (Media Cybernetics, Silver Springs, MD, USA)
as described [24].
Real-time reverse-transcriptase polymerase chain reaction
(qRT–PCR)
Total mRNA from the mouse liver was isolated using
the Trizol reagent from Invitrogen (Carlsbad, CA). Two
micrograms of total RNA were used for cDNA synthesis
using an RNeasy kit (QIAGEN) according to the manu-
facturer's instructions. Quantitative real-time SYBR
Green quantitative RT-PCR was performed using a
7900HT real-time PCR system (ABI, CA, USA) to deter-
mine the expression of target genes according to the
instructions of the SYBR Premix EX Taq (TaKaRa
Biotechnology, China). Data were normalized to glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) mRNA
as an endogenous control and analyzed using the ΔΔCt
method. Primer sequences are provided in Table 1.
Table 1 Primer sequence of Real-time PCR
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Western blotting
Expression of total c-Jun N-terminal kinases (JNK),
phospho-JNK (p-JNK), total P38 and phospho-P38
(p-P38) in liver were measured by Western blotting as
described [25]. Proteins were separated on 12.5% SDS-
PAGE gels and transferred onto nitrocellulose
membranes. Antibodies were purchased from Cell
Signaling Technology (USA). P38, p-P38, JNK, p-JNK
expression was analyzed using a rabbit monoclonal
antibody (1: 1000) primary antibody, and a rabbit-anti-
mouse IgG-HRP (1: 1000) secondary antibody. GAPDH
(1: 1000 dilution for the primary antibody and 1: 1000
dilution for the secondary antibody was used as an
endogenous control. Western blot bands were scanned
and quantified by densitometry analysis using an image
analyzer Quantity One System (Odyssey, USA).
Statistical evaluation
Statistical analyses were performed using SPSS 21.0 soft-
ware (Chicago, IL) and GraphPad Prism software
(GraphPad Software Inc). Data were presented as mean
values ± standard errors. The ANOVA test was used to
determine differences between groups comparing the in-
ternal variability of group with the variability among all
experimental groups. Multiple comparisons between the
groups were performed using S-N-K method as a post--
hoc test. P values <0.05 were considered statistically sig-
nificant. All assays were performed in triplicate.
Results
In this study, HFD mice treated with melatonin were
compared with HFD mice treated with water, and with
lean mice being either treated or not treated with mela-
tonin. Lean mice that were treated or not treated with
melatonin had similar weights, glucose metabolism, lipid
metabolism, and levels of inflammatory markers, so both
groups are referred to as controls.
Body weight and liver mass
As shown in Fig. 1A, HFD increased body weight and
liver mass compared with RD. [at 24w: (A) 53.11 ± 0.72
vs (B) 53.30 ± 0.60 vs (C) 37.25 ± 0.40 vs (D) 37.50 ±
0.39 g]. The average body weight of high fat diet fed
mice is ~42.4% more than the regular diet fed mice.
Administration of melatonin significantly reduced both
body weight by ~30.2% less than the HFD mice [at36w:
(A) 39.48 ± 0.74 vs (B) 56.56 ± 0.62 vs (C) 38.18 ± 0.45
vs (D) 38.01 ± 0.44 g]. Livers were removed upon sacri-
fice and liver mass was measured. As shown in Fig. 1B,
the liver mass of melatonin treated mice is ~ 33.9% less
than the HFD mice [(A) 1.93 ± 0.09 vs (B) 2.92 ± 0.19 vs (C)
1.48 ± 0.09 vs (D) 1.49 ± 0.10 g] (p < 0.01 between A and B).
Glucose and lipid metabolism
As shown in Table 2 and Fig. 2, after ANOVA test per-
formed among four groups and independent sample
T-test used between two groups as a post-hoc test with
ANOVA test. It was foundthat melatonin treatment
significantly reduced fasting plasma glucose (FPG)
(Fig. 2a), ALT (Fig. 2b), and LDL (Fig. 2c) in Group A
compared with Group B fed with HFD only, p < 0.01
between A and B.
Histological analyses of liver
HFD fed mice developed liver steatosis. By contrast,
HFD mice treated with melatonin showed a significantly
less liver steatosis (Fig. 3).
Inflammatory
The mRNA levels of pro-inflammatory cytokines includ-
ing tumor necrosis factor-α (TNF-α), IL-1β, and IL-6
significantly increased in the HFD group compared with
RD fed mice, and HFD mice treated with melatonin
demonstrated significantly lower expression of TNF-α,
Fig. 1 Effect of melatonin on body weight and liver mass. (A) Body weight (g) of HFD with melatonin, HFD, RD with melatonin and RD during
36 weeks, n = 6 mice/group. (B) Liver mass of HFD with melatonin, HFD, RD with melatonin and RD at the end of treatment, n = 6 mice/group.
*P < 0.05 for group A vs group B; #P < 0.05 for group B vs group D
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IL-1β, and IL-6 (Fig. 4). IL-10 and IKK-β were not
significantly different.
Furthermore, we evaluated the expression of P38 and
c-Jun N-terminal kinases (JNK) 1/2 in liver by Western
blotting (Fig. 5). HFD increased phosphorylated levels of
P38 and JNK1/2, which was reversed by treatment with
melatonin.
Discussion
Numerous studies have demonstrated that melatonin
treatment reduces body weight in both animal models
and human [26–29]. A recent study demonstrated that
melatonin has effects on inflammation, fat deposition,
and energy metabolism in ob/ob mice [30]. In this study,
we found that melatonin treatment for 12 weeks
significantly decreased body weight and liver weight in
HFD mice. Melatonin was also found to regulate glucose
metabolism. There are two membrane receptors of
melatonin called MT1 and MT2, which are G-protein-
coupled receptors, in the periphery [31]. Both receptors
are expressed in the islet of Langerhans and are involved
in the regulation of glucagon secretion from α-cells and
insulin secretion from β-cells [16, 32]. Several studies
indicate that activation of MT1 or MT2 leads to a
reduction in second messenger 3’,5’-cyclic adenosine
monophosphate (cAMP) or 3’,5’-cyclic guano-sine mono-
phosphate (cGMP) accompanied by reduced insulin
secretion [33, 34]. Consistent with this mechanism, we
found that melatonin treatment significantly reduced
HFD induced elevations in blood glucose.
Early experiments showed that treatment with mela-
tonin can improve dyslipidemia [15]. In patients with
NAFLD, treatment with melatonin (2-5 mg/day) for
14 months significantly reduced levels of triglycerides
(TG) and low density lipoprotein cholesterol (LDL-C)
compared with controls treated with Essentiale [35].
Treatment with melatonin for two weeks significantly
reduced free fatty acids (FFA) compared with placebo in
cigarette smokers [36]. A study assessing aluminium-
induced toxicity in a rat model found that melatonin
protected against toxic dyslipidemia by alleviating the
aluminum induced increases in total cholesterol (TC),
LDL-C, TG, oxidized LDL, and apolipoprotein B100
(apoB100) [37]. Pan et al [38] found that melatonin
Table 2 Effects of melatonin on fasting plasma glucose, serum
transaminase, and lipid levels
Group A Group B Group C Group D
FPG, mmol/L 5.03 ± 0.38* 8.45 ± 0.35# 4.71 ± 0.29 4.85 ± 0.33
HDL, mmol/L 1.71 ± 0.53 1.51 ± 0.39 2.05 ± 0.43 1.99 ± 0.37
LDL, mmol/L 0.24 ± 0.06* 1.57 ± 0.10# 0.28 ± 0.06 0.29 ± 0.03
TG, mmol/L 1.11 ± 0.35 1.06 ± 0.24 1.18 ± 0.15 1.24 ± 0.18
AST, IU/L 20.31 ± 4.41 20.01 ± 1.20 14.98 ± 4.39 13.35 ± 1.57
ALT, IU/L 24.33 ± 11.90* 60.80 ± 10.18# 13.01 ± 3.49 16.62 ± 2.00
Group A: HFD +MLT, Group B: HFD, Group C: RD +MLT, Group D: RD. FPG fasting
plasma glucose, HDL high-density cholesterol, LDL low-density cholesterol, TG
Triglycerides, AST aspartate aminotransferase and ALT Alanine aminotransferase.
*P < 0.05 for group A vs group B; #P < 0.05 for group B vs group D
Fig. 2 Effect of melatonin on fasting plasma glucose, serum transaminase, and lipid levels. (a) Fasting plasma glucose (FPG, mmol/L), *P < 0.05 vs
group A. (b) Alanine aminotransferase (ALT, IU/L) and aspartate aminotransferase (AST, IU/L). *P < 0.05 vs other 3 groups. (c) Triglycerides
(TG, mmol/L), low-density cholesterol (LDL-C, mmol/L) and high-density cholesterol (HDL-C, mmol/L). *P < 0.05 for group A vs group B; #P < 0.05
for group B vs group D
Sun et al. Lipids in Health and Disease  (2016) 15:202 Page 4 of 8
ameliorates NAFLD by lowering serum AST, ALT, liver
total cholesterol, and triglycerides in high-fat diet fed
rats. Consistently, in this study, we have demonstrated
that melatonin administration decreases serum LDL and
ALT and reduces the degree of hepatocyte steatosis.
To explore the possible mechanism of melatonin’s
beneficial effects on NAFLD, we measured mRNA levels
of pro-inflammatory makers and the active levels of
mitogen-activated protein kinase (MAPK) signaling.
Inflammation contributes to the progression of NAFLD
to NASH [5]. We found that melatonin treatment sig-
nificantly reduced the mRNA level of pro-inflammatory
cytokines including TNF-α, IL-1β, and IL-6, which were
increased in HFD fed mice. The expression of total
JNK1/2 and P38 were similar in four groups, but the
phosphorylated levels of P38 and JNK1/2 were increased
in HFD mice compared with RD fed mice. The activa-
tion of the JNK1/2 and P38 signaling molecules by HFD
was reduced by melatonin administration. There are
many signaling pathways involved in the progression of
hepatic steatosis with numerous interactions among the
different pathways. The MAPK signaling pathway is in-
volved in the regulation of inflammation and fatty acid
metabolism [39, 40]. HFD leads to inflammation and
weight gain, and melatonin treatment could alleviate the
inflammation as well as obesity caused by HFD. RD did
not lead to any disorders, so melatonin supplemental in
RD fed mice would have limited effects on changes in
Fig. 3 Histological analyses of liver steatosis. Representative images (400×) of H&E-stained (Upper) and Oil Red O-stained (Lower) liver sections
from (a) HFD with melatonin, (b) HFD, (c) RD with melatonin, and (d) RD
Fig. 4 Quantification of pro-inflammatory cytokines. qRT-PCR was conducted in order to analyze the expression of tumor necrosis factor-α
(TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-10 (IL-10), c-Jun N-terminal kinases (JNK), and inhibitor of nuclear factor
kappa-B kinase subunit beta (IKK-β). *P < 0.05 for group A vs group B; #P < 0.05 for group B vs group D
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weight, glucose metabolism, lipid metabolism, and in-
flammation status. Taken together, our data indicate that
melatonin affects the signaling pathways leading to
elevated inflammatory responses induced by HFD. We
hypothesize that the decreased levels of inflammation
after melatonin treatment could improve liver pathology
in NAFLD and inhibits progression to NASH.
This study had several limitations. Firstly, we did not rec-
ord the food intake of experimental animals, which was
one of the limitations of the study. However, a previous
study showed that melatonin treatment could reduce body
weight without affecting food intake [41]. And another
study demonstrated that ob/ob mice with melatonin ad-
ministration consumed more food than their genotype
counterparts without gaining weight [26]. The effect of
melatonin on food intake does need to be further explored.
Reduced body mass could lead to a reduction of
adiposity and ectopic accumulation of fat, thus reducing
hepatic steatosis. A reduction of steatosis, in turn, down-
regulates inflammatory markers. In our study, body mass
decreased with melatonin treatment, which could be ex-
plained possibly by the melatonin effects on body mass, or
other beneficial effects. However, we would also consider
the therapeutic effect of melatonin on NAFLD as a result
of both anti-inflammation and anti-obesity functions. Pre-
vious studies have shown the anti-inflammatory properties
of melatonin [10, 11]. In our study, we also found the
anti-inflammatory effects on mice fed with HFD, but not
on mice fed with regular diet. During the initiation and
progression of hepatic steatosis. The dysregulation of lipid
metabolism is frequently associated with an inflammatory
condition [42], and the elevated inflammatory status plays
an important role in the development of insulin resistance,
which in turn further promotes ectopic fat accumulation
in the liver, forming a vicious cycle [43].
Conclusion
This study concluded that the treatment with melatonin
could decrease body weight and ameliorate liver
pathology due to NAFLD in HFD induced obese mice.
Melatonin likely decrease inflammation via the
MAPK-JNK/P38 signaling pathway.
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